[REVISION HISTORY]

Eli Lilly retatrutide development and black market issues

Updated 8 times since CLSTR started tracking revisions of this situation.

What changed

2026-10-04 14:02 UTC → 2026-10-11 21:53 UTC · added ~~removed~~

In early August 2026, Eli Lilly announced that its experimental obesity treatment retatrutide achieved substantial weight-loss outcomes in two phase-3 trials. Participants lost up to 22.6% of body weight over 80 weeks in a study involving individuals with severe obesity and cardiovascular disease, while a separate study involving individuals with obesity but without diabetes saw average weight loss reach 28.3% at the highest dose. The drug’s triple-agonist approach—targeting GLP-1, GIP, and glucagon—may influence how the body utilizes energy rather than just suppressing appetite. Research into the drug, sometimes discussed in the context of GLP-3, continues to explore its potential for treating metabolic diseases by targeting multiple signaling pathways simultaneously. Positive results were specifically noted from the TRIUMPH-2 and TRIUMPH-3 studies reported in July 2026. By October 2026, further data confirmed the efficacy of the investigational therapy, noting that in studies involving patients with type 2 diabetes who were overweight or obese, participants lost an average of up to 20.8% of their body weight over 80 weeks. Clinical studies have indicated weight reductions of approximately 30 percent. Common side effects include nausea and diarrhea, and a small subgroup showed a higher incidence of serious cardiovascular events. Medical experts have also warned of risks associated with uncontrolled use, noting that off-label use for purely aesthetic purposes by individuals who are not clinically obese may lead to complications such as severe gastroparesis and paralytic ileus. Eli Lilly plans to seek FDA approval in the United States during the first quarter of 2027. To provide access, Lilly launched a compassionate-use program in the U.S. for adults with refractory obesity and at least two serious weight-related complications who are ineligible for ongoing trials. As the drug remains in the clinical trial phase without regulatory approval, counterfeit versions are flooding black markets. In the UK, illicit vials are reportedly being distributed through gyms, beauty salons, hairdressers, social media, and street vendors. Eli Lilly has initiated legal action against various U.S. entities, including compounding pharmacies and medical spas, for the illegal sale of black-market retatrutide.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.